A Review of Difficult-to-Treat Rheumatoid Arthritis: Definition, Clinical Presentation, and Management

• Published in: Current rheumatology reports 2023-12, Vol.25 (12), p.285-294
• Main Authors: Conran, Carly, Kolfenbach, Jason, Kuhn, Kristine, Striebich, Christopher, Moreland, Larry
• Format: Article
• Language: English
• Subjects: Medicine; Medicine & Public Health; Rheumatology; Topical Collection on Rheumatoid Arthritis
• ISSN: 1523-3774; 1534-6307
• DOI: 10.1007/s11926-023-01117-6

Purpose of Review A subset of patients with rheumatoid arthritis (RA) who fail multiple biologic therapies are deemed to have “difficult-to-treat” (D2T) RA. In 2021, a European Alliance of Associations for Rheumatology (EULAR) task force proposed a clinical definition of D2T RA. Here we review RA phenotypes and clinical assessment of RA, propose a different definition of D2T RA, discuss possible D2T RA risk factors, and summarize existing literature on the management of D2T RA. Recent Findings High disease activity at the time of diagnosis or prior to treatment with a biologic is associated with the development of D2T RA. Prolonged time from diagnosis to beginning treatment has been consistently associated with the development of D2T RA. Other clinical factors such as burden of disease, extraarticular disease, obesity, smoking, pain, fatigue, and psychological conditions have inconsistent associations with D2T RA according to current literature. Summary D2T RA is a relatively new concept that represents an area of great need for research regarding the characterization of those with the disease as well as how best to treat the disease. With this gained knowledge, rheumatologists will be able to better identify patients at the time of diagnosis that are likely to develop D2T RA to help guide management.